Industry News
Pharmaceutical Industry News
Omicron spurs Celltrion to accelerate development of nebulized COVID-19 antibody cocktail
Omicron spurs Celltrion to accelerate development of nebulized COVID-19 antibody cocktail ntaylor Tue, 11/30/2021 - 09:08
Aspen closes in on Africa license for Johnson & Johnson’s COVID-19 vaccine
Aspen closes in on Africa license for Johnson & Johnson's COVID-19 vaccine fkansteiner Tue, 11/30/2021 - 09:05
Chinese firms win subcutaneous checkpoint inhibitor approval, beating global heavyweights to new opportunity
Chinese firms win subcutaneous checkpoint inhibitor approval, beating global heavyweights to new opportunity ntaylor Tue, 11/30/2021 - 09:05
EpiPen rival Kaléo snapped up in $310M deal by investor group
EpiPen rival Kaléo snapped up in $310M deal by investor group jkeenan Tue, 11/30/2021 - 08:47
¿Las vacunas funcionan para la variante ómicron?
Una “mezcla tipo Frankenstein” de mutaciones suscita preocupación, pero la variante puede seguir siendo vulnerable a las vacunas actuales. Si no es así, serán necesarias revisiones.
COVID-19 tracker: FDA advisory group will discuss Merck antiviral; Companies test vaccines against new variant
COVID-19 tracker: FDA advisory group will discuss Merck antiviral; Companies test vaccines against new variant elucas Mon, 11/29/2021 - 15:31
COVID-19 tracker: Omicron variant was in Europe before it was found in South Africa
COVID-19 tracker: Omicron variant was in Europe before it was found in South Africa elucas Mon, 11/29/2021 - 15:31
COVID-19 tracker: First omicron case detected in US
COVID-19 tracker: First omicron case detected in US elucas Mon, 11/29/2021 - 15:31
COVID-19 tracker: Biden’s winter plan includes tighter travel rules and free at-home tests
COVID-19 tracker: Biden's winter plan includes tighter travel rules and free at-home tests elucas Mon, 11/29/2021 - 15:31
Antiviral Covid-19 Pills Are Coming. Will There Be Enough Tests?
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
Pfizer boosts Paxlovid manufacturing capacity as Merck’s rival COVID pill hits surprise efficacy setback
Pfizer boosts Paxlovid manufacturing capacity as Merck’s rival COVID pill hits surprise efficacy setback aliu Mon, 11/29/2021 - 11:38
Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron
Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron fkansteiner Mon, 11/29/2021 - 11:15
Pfizer, Moderna, J&J and AstraZeneca assess omicron’s effect on their COVID-19 vaccines
Pfizer, Moderna, J&J and AstraZeneca assess omicron's effect on their COVID-19 vaccines kdunleavy Mon, 11/29/2021 - 10:55
FDA deals another blow to Fennec’s hearing loss treatment for pediatric cancer patients
FDA deals another blow to Fennec’s hearing loss treatment for pediatric cancer patients jkeenan Mon, 11/29/2021 - 10:31
Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China’s latest cost squeeze
Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeeze aliu Mon, 11/29/2021 - 10:27
U.K. looks to shed $287M vaccine production facility to recoup costs, report says
U.K. looks to shed $287M vaccine production facility to recoup costs, report says jkeenan Mon, 11/29/2021 - 09:24
UK looks to shed $287M vaccine production facility to recoup costs, report says
UK looks to shed $287M vaccine production facility to recoup costs, report says jkeenan Mon, 11/29/2021 - 09:24
Former Insys execs ordered to pay $48.3 million in restitution in Subsys opioid trial
Former Insys execs ordered to pay $48.3 million in restitution in Subsys opioid trial fkansteiner Mon, 11/29/2021 - 09:15
Former Insys execs ordered to pay $48.3M in restitution in Subsys opioid trial
Former Insys execs ordered to pay $48.3M in restitution in Subsys opioid trial fkansteiner Mon, 11/29/2021 - 09:15
Will the Vaccines Stop Omicron? Scientists Are Racing to Find Out.
A “Frankenstein mix” of mutations raises concerns, but the variant may remain vulnerable to current vaccines. If not, revisions will be necessary.